Primary non-Hodgkin’s lymphoma of the lung

Ferraro, Pasquale; Trastek, Victor F.; Adlakha, Harkiran; Deschamps, Claude; Allen, Mark S.; Pairolero, Peter C.

doi:10.1016/s0003-4975(99)01535-0

Cited by 225 publications

(221 citation statements)

References 21 publications

Supporting

Mentioning

185

Contrasting

Unclassified

Order By: Relevance

“…[14][15][16][17][18][19][20][21][22][23][24][25] Two outcome studies, 26 20 In patients with MALT type lymphoma the overall survival at one year was 91%, the overall survival at five years was 68% and the overall survival at ten years was 53%. These data were weighted taking into account the fact that this lymphoma is an indolent disease usually with a long natural course, and that it is a multifocal disease in which a radical resection is not easy to perform.…”

Section: Primary Lung Lymphomasmentioning

confidence: 99%

Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

Zinzani¹,

Martelli²,

Poletti³

et al. 2008

Haematologica

View full text Add to dashboard Cite

Extranodal non-Hodgkin's lymphomas constitute 20-25% of overall non-Hodgkin's lymphomas cases and can be managed with very different therapeutic strategies. Therefore, the Italian Society of Hematology and the two affiliate societies (the Italian Society of Experimental Hematology and the Italian Group of Bone Marrow Transplantation) appointed a panel of experts to produce clinical practice-guidelines for the management of these conditions. Primary lung and mediastinal lymphomas were the objective of this part of the project. The panel of experts produced the following key recommendations that were graded according to the strength of evidence and clinical judgement. The first-line therapy for non-MALT primary lung non-Hodgkin's lymphomas should include anthracycline-based chemotherapy with CHOP or CHOP-like, MACOP-B or MACOP-B-like regimens (grade D). Rituximab association with chemotherapy needs to be evaluated within approved clinical trials. Second-line therapy with high-dose chemotherapy and autologous stem cell transplantation is recommended (grade B). In patients with MALT primary lung non-Hodgkin's lymphomas, the recommended first-line therapy should include chlorambucil, CHOP, CHOP-like or fludarabine-containing regimens (grade B). Radiotherapy is to be reserved for patients with a unique, small lesion in a poorly mobile site and with contraindication to surgery (grade D). Rituximab should be administered only within approved clinical trials. For treatment of primary mediastinal large B-cell lymphomas, the recommended first-line therapy is a chemotherapy and radiotherapy association (grade B). An anthracycline-based chemotherapy with CHOP, MACOP-B or VACOP-B is recommended (grade B). Rituximab combination with chemotherapy is highly suggested but only for patients enrolled into approved clinical trials. Patients with an inadequate early response should be candidates for early intensification with high-dose chemotherapy (grade C). Patients with refractory or relapsed disease should undergo rescue programs including intensive, non-cross-resistant debulking treatment followed, in chemosensitive patients, by high-dose chemotherapy and autologous stem cell transplantation (grade B).

show abstract

Section: Primary Lung Lymphomasmentioning

confidence: 99%

Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation

Zinzani¹,

Martelli²,

Poletti³

et al. 2008

Haematologica

View full text Add to dashboard Cite

show abstract

“…Postoperative chemotherapy did not improve survival. No prognostic factors could be identified [144]. Zinzani and coworkers reported a 100% 6-year survival rate in patients with stage I disease treated with chemotherapy (n = 8) , surgery (n = 2), or both (n = 2) [145].…”

Section: Lungmentioning

confidence: 99%

Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue

et al. 2006

View full text Add to dashboard Cite

show abstract

“…3) Bronchoscopy is thought to be of limited value, as for diagnosis of PPL because endobronchial changes in PPL are rare. 3,9) However, in the present case, our diagnosis was made via bronchoscopy. Therefore, even if malignant lymphoma is suspected on images, bronchoscopy may be effective.…”

Section: Discussionmentioning

confidence: 69%

A Case of Primary Pulmonary Diffuse Large B-Cell Lymphoma Diagnosed by Transbronchial Biopsy

Yoshino

Hirata

Takeuchi

et al. 2015

ATCS

View full text Add to dashboard Cite

Primary non-Hodgkin’s lymphoma of the lung

Cited by 225 publications

References 21 publications

Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue

A Case of Primary Pulmonary Diffuse Large B-Cell Lymphoma Diagnosed by Transbronchial Biopsy

Contact Info

Product

Resources

About